Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells

Objective To establish an integrated feeder-free platform for in vitro expansion and gene editing to tackle the major challenges in clinical applications of cryopreserved primary human natural killer (NK) cells in terms of low expansion efficiency, technical difficulty in genetic modification and sa...

Full description

Saved in:
Bibliographic Details
Main Author: CHI Xiaolin, YUN Shaowei, YAO Yao, RAO Shuquan
Format: Article
Language:zho
Published: Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2025-05-01
Series:Jichu yixue yu linchuang
Subjects:
Online Access:https://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2025-45-5-608.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849424995990634496
author CHI Xiaolin, YUN Shaowei, YAO Yao, RAO Shuquan
author_facet CHI Xiaolin, YUN Shaowei, YAO Yao, RAO Shuquan
author_sort CHI Xiaolin, YUN Shaowei, YAO Yao, RAO Shuquan
collection DOAJ
description Objective To establish an integrated feeder-free platform for in vitro expansion and gene editing to tackle the major challenges in clinical applications of cryopreserved primary human natural killer (NK) cells in terms of low expansion efficiency, technical difficulty in genetic modification and safety concerns. Methods A non-viral CRISPR-Cas9 ribonucleoprotein (RNP)-based multiplex gene editing system was developed through systematic optimization of culture medium and nucleofection conditions. Cell phenotype (CD56+CD3-), viability, editing efficiency, and tumor-killing activity were evaluated via flow cytometry and cytotoxicity assays. Results The number of NK cells achieved 5 000-fold expansion over 25 days while maintaining high purity (CD56+CD3- >95%) and viability (>90%).Post-thawing viability (>80%) and tumor-killing capacity were preserved.Cas9 RNP delivery enabled efficient dual knockout of NKG2A and CISH immune checkpoint genes (>80%), significantly enhanced cytotoxicity against K562 tumor cells (P<0.05). Conclusions Compared to viral vectors, the non-viral strategy eliminates genomic integration risks and reduces off-target effects. This result may provide a safe and efficient technical platform for clinical application of NK cell immunotherapy and potentially encourage application of multiplex gene editing in cancer therapy.
format Article
id doaj-art-a08d941db4e94c2ebf3855d8b7467f16
institution Kabale University
issn 1001-6325
language zho
publishDate 2025-05-01
publisher Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
record_format Article
series Jichu yixue yu linchuang
spelling doaj-art-a08d941db4e94c2ebf3855d8b7467f162025-08-20T03:29:57ZzhoInstitute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.Jichu yixue yu linchuang1001-63252025-05-0145560861510.16352/j.issn.1001-6325.2025.05.0608Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cellsCHI Xiaolin, YUN Shaowei, YAO Yao, RAO Shuquan01. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020;;2. Tianjin Institutes of Health Sciences, Tianjin 301600, ChinaObjective To establish an integrated feeder-free platform for in vitro expansion and gene editing to tackle the major challenges in clinical applications of cryopreserved primary human natural killer (NK) cells in terms of low expansion efficiency, technical difficulty in genetic modification and safety concerns. Methods A non-viral CRISPR-Cas9 ribonucleoprotein (RNP)-based multiplex gene editing system was developed through systematic optimization of culture medium and nucleofection conditions. Cell phenotype (CD56+CD3-), viability, editing efficiency, and tumor-killing activity were evaluated via flow cytometry and cytotoxicity assays. Results The number of NK cells achieved 5 000-fold expansion over 25 days while maintaining high purity (CD56+CD3- >95%) and viability (>90%).Post-thawing viability (>80%) and tumor-killing capacity were preserved.Cas9 RNP delivery enabled efficient dual knockout of NKG2A and CISH immune checkpoint genes (>80%), significantly enhanced cytotoxicity against K562 tumor cells (P<0.05). Conclusions Compared to viral vectors, the non-viral strategy eliminates genomic integration risks and reduces off-target effects. This result may provide a safe and efficient technical platform for clinical application of NK cell immunotherapy and potentially encourage application of multiplex gene editing in cancer therapy.https://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2025-45-5-608.pdfnatural killer cells|gene editing|crispr-cas9 non-viral delivery
spellingShingle CHI Xiaolin, YUN Shaowei, YAO Yao, RAO Shuquan
Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells
Jichu yixue yu linchuang
natural killer cells|gene editing|crispr-cas9 non-viral delivery
title Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells
title_full Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells
title_fullStr Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells
title_full_unstemmed Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells
title_short Development of an integrated platform for in vitro expansion and CRISPR-Cas9 gene editing of umbilical cord blood NK cells
title_sort development of an integrated platform for in vitro expansion and crispr cas9 gene editing of umbilical cord blood nk cells
topic natural killer cells|gene editing|crispr-cas9 non-viral delivery
url https://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2025-45-5-608.pdf
work_keys_str_mv AT chixiaolinyunshaoweiyaoyaoraoshuquan developmentofanintegratedplatformforinvitroexpansionandcrisprcas9geneeditingofumbilicalcordbloodnkcells